A Small-Molecule SUMOylation Inhibitor Activates Antitumor Immune Responses and Potentiates Immune Therapies in Preclinical Models

Ex vivo treatment of mouse and human dendritic cells promoted their IFN1-dependent activation, and vaccination studies in mice demonstrated stimulation of antigen cross-presentation and T cell priming in vivo.